Abstract
Background Folate Receptor Alpha (FRa) is an immunogenic protein that is over-expressed in breast, endometrial and ovarian cancer (OC). In fact, FRa expression in malignant cells is 20-fold higher compared to normal cells. We have begun a phase 1 clinical trial with E39, an HLA-A2 restricted, FRa peptide vaccine. The vaccine is administered in the adjuvant setting to prevent recurrences in high-risk, endometrial and OC patients (pts) rendered clinically diseasefree with standard-of-care therapy. Here, we summarize toxicity and in vivo immunologic responses after enrollment of three dose cohorts.
Highlights
Folate Receptor Alpha (FRa) is an immunogenic protein that is over-expressed in breast, endometrial and ovarian cancer (OC)
HLA-A2+ pts are enrolled into the vaccine group (VG) while HLA-A2- pts are being followed prospectively as an untreated control group (CG)
Six monthly intradermal inoculations (R1-R6) of either 100mcg, 500mcg, or 1000mcg of E39 + 250 mcg GMCSF immunoadjuvant are administered during the primary vaccine series (PVS)
Summary
John S Berry, Erika J Schneble1*, Alfred F Trappey, Timothy J Vreeland, Guy T Clifton, Diane F Hale, Alan K Sears, Sathibalan Ponniah, Elizabeth A Mittendorf, George E Peoples. From Society for Immunotherapy of Cancer 28th Annual Meeting National Harbor, MD, USA. From Society for Immunotherapy of Cancer 28th Annual Meeting National Harbor, MD, USA. 8-10 November 2013
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call